Investors Contact Payment Careers Research Request
Interpace Biosciences, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Diagnostics
  • Pharma Solutions
    • Overview
    • Biomarkers Solutions
    • Genomics Services/
      Molecular Dx
    • Anatomic Path, Flow, and Cytogenetics
    • Integrated Biorepository
    • Bioinformatics Solutions
    • SpatialPlex™ Services
  • Support
  • Labs
  • News & Media
    • Press Releases
    • In The News
    • Presentations
    • Events
  • Investors
  • Contact
  • Payment
  • Careers
  • Research Request

Press Releases

Investors
  • Overview
  • News / Events
    • Overview
    • Press Releases
    • In The News
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • In The News
  • IR Calendar
  • Email Alerts

Interpace Biosciences Announces First Quarter 2022 Financial and Business Results

May 16, 2022

Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience

May 11, 2022

Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results

Mar 31, 2022

Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests

Feb 22, 2022

Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests

Jan 28, 2022

Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director

Jan 27, 2022

Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering

Jan 12, 2022

Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering

Jan 3, 2022

Interpace Biosciences Announces Third Quarter 2021 Financial and Business Results

Nov 10, 2021

Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans

Nov 2, 2021
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...22
© 2022 Interpace Biosciences, Inc. All Rights Reserved.
Privacy Policy HIPAA Privacy Disclaimer Sitemap
We Own Our Future Logo
  • Linkedin